Wells Fargo & Company Issues Positive Forecast for Healthpeak Properties (NYSE:DOC) Stock Price

Healthpeak Properties (NYSE:DOC) had its price target increased by Wells Fargo & Company from $20.00 to $22.00 in a report published on Wednesday morning, Marketbeat reports. The brokerage currently has an equal weight rating on the real estate investment trust’s stock.

A number of other research analysts also recently commented on the stock. Evercore lowered shares of Healthpeak Properties from an “outperform” rating to an “in-line” rating and set a $21.00 price objective on the stock. in a report on Monday, May 11th. BMO Capital Markets boosted their target price on shares of Healthpeak Properties from $20.00 to $24.00 and gave the company an “outperform” rating in a report on Monday, June 15th. Citigroup upped their price target on shares of Healthpeak Properties from $17.50 to $20.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Morgan Stanley reaffirmed an “equal weight” rating and set a $22.00 price target (up from $20.00) on shares of Healthpeak Properties in a research note on Thursday, June 11th. Finally, UBS Group lifted their price target on shares of Healthpeak Properties from $19.00 to $21.50 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Four research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat.com, Healthpeak Properties has an average rating of “Hold” and an average price target of $20.62.

Healthpeak Properties Price Performance

Shares of NYSE:DOC opened at $21.73 on Wednesday. The company has a market cap of $14.98 billion, a P/E ratio of 67.92, a P/E/G ratio of 3.36 and a beta of 1.02. The business has a fifty day simple moving average of $20.36 and a 200-day simple moving average of $18.17. Healthpeak Properties has a 52 week low of $15.70 and a 52 week high of $22.13. The company has a quick ratio of 2.96, a current ratio of 2.96 and a debt-to-equity ratio of 1.15.

Healthpeak Properties (NYSE:DOC) last released its earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.02. Healthpeak Properties had a return on equity of 2.61% and a net margin of 7.73%.The firm had revenue of $752.95 million for the quarter, compared to the consensus estimate of $694.59 million. During the same period in the prior year, the business posted $0.46 earnings per share. The firm’s revenue for the quarter was up 7.1% compared to the same quarter last year. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. Equities research analysts forecast that Healthpeak Properties will post 1.75 EPS for the current year.

Healthpeak Properties Announces Dividend

The company also recently announced a monthly dividend, which will be paid on Friday, September 25th. Stockholders of record on Monday, September 14th will be issued a dividend of $0.1017 per share. The ex-dividend date is Monday, September 14th. This represents a c) dividend on an annualized basis and a dividend yield of 5.6%. Healthpeak Properties’s payout ratio is presently 381.25%.

Insider Transactions at Healthpeak Properties

In related news, insider Scott R. Bohn sold 10,989 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $19.45, for a total transaction of $213,736.05. Following the completion of the sale, the insider owned 7,636 shares of the company’s stock, valued at approximately $148,520.20. This represents a 59.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.23% of the company’s stock.

Institutional Investors Weigh In On Healthpeak Properties

Several institutional investors have recently bought and sold shares of the business. CX Institutional raised its position in Healthpeak Properties by 6.1% in the second quarter. CX Institutional now owns 11,003 shares of the real estate investment trust’s stock worth $235,000 after acquiring an additional 633 shares in the last quarter. Fiduciary Trust Co grew its stake in shares of Healthpeak Properties by 4.9% in the 3rd quarter. Fiduciary Trust Co now owns 13,807 shares of the real estate investment trust’s stock worth $264,000 after purchasing an additional 644 shares during the last quarter. Patton Fund Management Inc. raised its holdings in shares of Healthpeak Properties by 5.2% in the 4th quarter. Patton Fund Management Inc. now owns 13,002 shares of the real estate investment trust’s stock worth $209,000 after purchasing an additional 648 shares in the last quarter. Quadrant Capital Group LLC lifted its stake in Healthpeak Properties by 1.9% during the third quarter. Quadrant Capital Group LLC now owns 37,650 shares of the real estate investment trust’s stock valued at $721,000 after purchasing an additional 718 shares during the last quarter. Finally, Quantum Portfolio Management LLC lifted its stake in Healthpeak Properties by 2.5% during the first quarter. Quantum Portfolio Management LLC now owns 29,372 shares of the real estate investment trust’s stock valued at $483,000 after purchasing an additional 728 shares during the last quarter. 93.57% of the stock is currently owned by hedge funds and other institutional investors.

About Healthpeak Properties

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.